Close

Jefferies Downgrades Regeneron Pharma (REGN) to Hold, Sees Limited Eylea Upside

Go back to Jefferies Downgrades Regeneron Pharma (REGN) to Hold, Sees Limited Eylea Upside

Brean Capital Downgrades Regeneron Pharma (REGN) to Hold

January 17, 2013 8:23 AM EST

Brean Capital downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Hold saying it would be increasingly difficult for the company to substantially beat consensus as it had quite easily throughout 2012, regardless of a new indication and ex-U.S. approvals.

For an analyst... More

Baird Releases Bullish Note on Regeneron (REGN), Eylea Taking Share

January 15, 2013 2:23 PM EST

Today analysts a Baird put out a very bullish note on Regeneron Pharma (NASDAQ: REGN). In the note, analysts reiterated an Outperform rating and raised thier price target to $205.00 (from $176.00). Analyst also noted strong uptake of Eylea, which continues to take share from Lucentis... More